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In August and September of this year, the world will turn its attention to Rio de Janiero, Brazil, for the 
2016 Summer Olympic and Paralympic Games. Of interest to physiatrists, the Paralympic Games will 
take place from September 7-18, with an estimated total of 4 billion viewers. In the United States, for the 
first time in history, the Summer Games will be broadcast over a total of 66 hours on NBCUniversal. The 
Paralympic Games represent the pinnacle of elite sport for athletes with disabilities, while also changing 
perceptions around the importance of grassroots sport and physical activity opportunities for the disability 
community more broadly.  
 
It is no secret that the planning and preparation for the Rio Games has brought with it a number of 
challenges – the Zika virus, water quality, construction delays and the oft tenuous state of the Brazilian 
political system, to name a few. In some respects, these challenges are important as they stimulate 
discourse about the future of the Olympic and Paralympic Movement. In Paralympic sport, some of our 
current and most salient challenges are rooted in principles of sports medicine and science, as outlined 
below. Since it is imperative to uphold the highest standards of athlete health and safety at the Games, 
this presents an unparalleled opportunity for the voice of physiatrists to come to the fore. As experts in 
disability and functional performance, neurologic and musculoskeletal rehabilitation, and sports medicine, 
we are uniquely suited to make an important and timely impact on Paralympic sport. Here we provide a 
snapshot of what to watch out for in Rio.  
 
Prosthetic Use in Amputee Track and Field 
The use of cutting-edge prosthetics in amputee sport initially gained global attention through the story of 
Oscar Pistorius – the first amputee to compete in both the Olympic and Paralympic Games in London, 
2012. Since that time, amputee athletes have sought to compete in both disability-specific and able-
bodied sport, transcending stereotypes and perceived societal limitations. Most recently, a German long 
jumper and single below knee amputee, Markus Rehm, has garnered international notoriety. At the 2015 
Doha International Paralympic Committee (IPC) Athletics World Championships, Rehm jumped a length 
of 8.40 meters, making him the new IPC world record holder [1]. Lesser known, however, is that this 
same jump would have made him a gold medalist at the London 2012 Olympic Games. In his attempt to 
compete in able-bodied track and field, Rehm recently underwent biomechanics testing at the German 
Sport University of Cologne. The results of the testing were inconclusive on whether he has an advantage 
over his able-bodied counterparts. Given that the International Association of Athletics Federations (IAAF) 
rules require him to prove that he has no advantage, he remains barred from able-bodied competition 
until further evidence is brought to the fore [2]. Looking ahead, it is clear that Paralympic athletes will 
continue to challenge concepts of what constitutes an appropriate, and fair, use of technology, versus 
unfair performance enhancement. As with all cutting edge technologies, this pushes us out of our comfort 
zone and begs the question – what will the future bring?  
 
Anti-Doping Challenges 
Prior to the Olympic and Paralympic Games, doping in sport inevitably gains attention as athletes push 
the envelope to enhance performance, sometimes through the use of prohibited substances or methods. 
In Paralympic sport, issues related to an athlete’s disability may, at times, lead to unique and complex 
challenges related to sample collection, the interpretation of results, and the granting of therapeutic use 
exemptions (TUEs) that are central to conducting a rigorous testing program. For example, in 2014 a 
paper was published noting that several Japanese athletes had tested positive for glycerol – a substance 
that is prohibited given its potential for use as a masking agent [3]. Upon further investigation, it was 
discovered that these positive tests were due to the athletes’ use of a glycerol-containing lubricant for 
self-catheterization [3]. Shortly thereafter, the World Anti-Doping Agency (WADA) testing standards were 
adjusted to increase the urine threshold value that constitutes a positive test, making this error unlikely to 
occur in the future. In the lead-up to Rio, all athletes have been cautioned against the use of glycerol-
containing lubricants for urine sample collection. Additionally, the Rio Paralympic village polyclinic and 
venue medical stations, as well as all doping control stations, will stock only lubricants that do not contain 
glycerol. As the performances of elite Olympians and Paralympains remain under scrutiny from an anti-
doping perspective, considerations such as this, which uniquely impact athletes with a disability, must be 
taken into account to ensure fair and equitable competition. 
 
Use of Botulinum Toxin and Potential Impact on Classification 
For physiatrists, it is commonly known that botulinum toxin is a standard treatment for spasticity caused 
by central neurologic injury such as cerebral palsy, traumatic brain injury, or stroke. Botox blocks the 
release of acetylcholine at the neuromuscular junction, thereby inhibiting the reflex muscle contraction 
that is the hallmark of spasticity [4]. From a functional standpoint, in appropriate candidates, therapeutic 
botulinum toxin may enable increased range of motion and reduce painful spasticity, however with a 
trade-off of causing motor weakness. Additionally, from a global perspective, botulinum toxin is often seen 
as a “luxury” treatment that is readily available only within higher-resourced health care systems. In 
Paralympic sport, concern has been raised regarding the use of botulinum toxin by athletes in order to 
unfairly improve performance. Currently, little objective evidence exists to justify this claim, although it has 
prompted concern from athletes and coaches, particularly those from resource-limited settings. For 
example, a wheelchair racer with cerebral palsy who has not yet undergone treatment with botulinum 
toxin may be classified as a T33, characterized by mild upper extremity spasticity and resultant 
asymmetry in propulsion. Shortly thereafter, he/she maybe undergo treatment, and in follow-up, present 
with the function of an athlete in class T34, characterized by minimal upper extremity spasticity and 
symmetry in propulsion. Should this athlete be re-classified post-botulinum toxin injection? Under the 
current regulations in some sports, an athlete is to inform the Head of Classification of any medical 
intervention that may affect his or her impairment, in which case the athlete is requested to present for re-
classification. However, there is a need for further standardization. Additionally, as botulinum toxin is 
currently not a substance on the World Anti-Doping Agency Prohibited List, its use cannot be objectively 
monitored through the therapeutic use exemption (TUE) process. As medical and scientific leaders in 
Paralympic sport, we must be cognizant of these challenges and strive to uphold the rights of all athletes, 
including those from under-resourced regions throughout the Movement [5].  
 
Concussion and its Impact on Paralympians 
Concussion is a very important topic in sports medicine, with increasing resources being committed to the 
expansion of research, clinical care, and educational initiatives to potentially reduce its incidence and to 
provide better treatment paradigms. The next major update on concussion in sports science is expected 
at the 5th International Consensus Conference on Concussion in Sport, due to take place in Berlin in 
October 2016. Within this context and from a historical perspective, little attention has been placed on the 
unique needs of Paralympic athletes, for whom the risk of concussion in sport is of equal concern. 
Several categories of Paralympic sport, for example, those uniquely developed for athletes with visual 
impairment (e.g. football 5-a-side) and those that take place a high speeds (e.g. Para alpine sit skiing) 
show a particularly high incidence of concussion [6,7]. Additionally, large portions of the SCAT3 (Sport 
Concussion Assessment Tool 3rd Edition) are not useful for athletes who use wheelchairs or with baseline 
balance deficits, and little is known regarding how the effect of concussion may be unique in athletes with 
central neurologic injury such as cerebral palsy, stroke, or traumatic brain injury. At the Rio 2016 
Paralympic Games, the IPC Injury and Illness Surveillance Study will again be conducted to provide 
baseline epidemiologic data regarding injuries and illnesses in Paralympic sport, with a goal to reduce 
their incidence [8]. This coming iteration of the study will be expanded to include additional details 
regarding concussion, thus providing novel data regarding risk factors at the Paralympic Games. Given 
the growth of Paralympic sport participants, further longitudinal, prospective studies are urgently needed 
to discern the unique needs of athletes with disabilities related to the prevention, incidence, diagnosis, 
and treatment of concussion.    
 
Autonomic Dysreflexia and Boosting 
For decades, the practice of “boosting” has been under scrutiny in Paralympic sport. Boosting is the 
intentional induction of autonomic dysreflexia for unfair performance enhancement by athletes with high 
thoracic and cervical spinal cord injury, and it is strictly prohibited by the IPC due to its inherent health 
risks. Since 2008, the IPC has implemented a testing program for boosting in major Paralympic 
competition, with the goal of deterring its practice [9]. Historically, systolic blood pressure (SBP) was 
utilized as a proxy marker for boosting. Athletes were tested just prior to competition, and a SBP reading 
of ≥180 mmHg was considered a “positive” test. Over time, the strengths and limitations of this testing 
paradigm have been evaluated. From the years 2008-2015, a total of 159 tests were conducted, none of 
which were positive. Additionally, it was noted that athletes could be dysreflexic with SBP levels much 
less than 180 mmHg. Utilizing historic data of pre-competition baseline SBPs in athletes with spinal cord 
injury, and supported by recent research findings [10], the IPC Governing Board (upon recommendation 
of the IPC Medical Committee) has recently amended its rules to lower this threshold for a “positive” test 
to >160 mmHg, effective immediately and to be implemented in Rio [8]. The primary goal of this program 
is to deter athletes from engaging in the practice of boosting given its inherent dangers, and to raise 
awareness regarding the importance of self-monitoring amongst athletes who may be susceptible to 
autonomic dysreflexia [11].  
 
Conclusion  
The Rio Paralympics will undoubtedly present exciting and cutting-edge performances from a diverse 
spectrum of athletes with disabilities. Competing and working within an environment such as Rio is likely 
to add complexity to issues such as infection control, accessibility, and safety. Although it is difficult to 
estimate the magnitude of the impact of these challenges, it is clear that in some respects athletes with 
disabilities may be disproportionately impacted. The same will likely be said for the Paralympic Games in 
Pyeongchang in 2018, or Tokyo in 2020; each Paralympic Games will present unique challenges, and 
opportunities, for both athletes and team physicians.  
 
Although the topics outlined in this article will push our limits in providing optimal care to Paralympians, 
historically, the lessons learned from past Paralympic games have translated into future advances in 
sports medicine and science, benefiting athletes with disabilities across a spectrum of athletic ability. 
Perhaps, in the next 2 or 3 Paralympic games, athletes will be utilizing sports prostheses made from a 3D 
printer, or an investigator will develop a specialized sideline assessment for concussion in athletes with 
dyskinetic cerebral palsy. As sports physicians, our charge is to innovate and to develop evidence that 
promotes athletes’ health and performance.  Further, as the physiatric members of the team of 
physicians, our collective voice is essential to maintain athletes’ health and function in the presence of a 
wide range of disabilities. Paralympic athletes are watching. Indeed, the entire world will be watching!  
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